4.6 Article

Adenosine A2A receptors in secondary progressive multiple sclerosis: a [11C]TMSX brain PET study

期刊

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
卷 33, 期 9, 页码 1394-1401

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/jcbfm.2013.85

关键词

A2A-receptor; adenosine; DTI; multiple sclerosis; PET

资金

  1. Academy of Finland
  2. Merck Serono S.A.-Geneva, Switzerland
  3. branch of Merck Serono S.A. Geneva, Switzerland
  4. Turku University Hospital
  5. Instrumentarium Science Foundation
  6. Novartis
  7. Roche
  8. Biogen Idec
  9. Orion-Pharma
  10. GE Healthcare Finland Ltd
  11. Bayer-Schering
  12. Sigrid Juselius Foundation
  13. GE Healthcare
  14. Merck Serono

向作者/读者索取更多资源

In this study, positron emission tomography (PET) imaging with a radioligand to adenosine A2A receptors (A2AR)-a potent regulator of inflammation-was used to gain insight into the molecular alterations in normal-appearing white matter (NAWM) and gray matter (GM) in secondary progressive multiple sclerosis (SPMS). Normal-appearing white matter and GM, despite seeming normal in conventional mangnetic resonance imaging (MRI), are important loci of widespread inflammation, neuronal damage, and source of progressive disability in multiple sclerosis (MS). Dynamic PET imaging using A2AR-specific [C-11]TMSX and brain MRI with diffusion tensor imaging were performed to eight SPMS patients and seven healthy controls. Distribution volumes (V-T) of [C-11]TMSX were analyzed from 13 regions of interest using Logan plot with arterial plasma input. The SPMS patients had significantly increased [C-11]TMSX-VT in NAWM compared with controls (mean (s.d.): 0.55 (+/- 0.08) vs. 0.45 (+/- 0.05); P = 0.036). Both the increased VT and the decreased fractional anisotropy (FA) in NAWM were associated with higher expanded disability status scale (EDSS) scores (P = 0.030 and P = 0.012, respectively), whereas the T2-lesion load of SPMS patients did not correlate with EDSS. This study shows, that A2ARs are increased in the brain of SPMS patients, and that [C-11]TMSX-PET provides a novel approach to learn about central nervous system pathology in SPMS in vivo.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据